Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria:~* Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.~Severity of disease meeting all of the following three criteria:~* PASI score of 12 or greater,~* Investigator's Global Assessment (IGA) score of 3 or greater~* Total body surface area (BSA) affected of 10% or greater.~* Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy.~Exclusion criteria:~* Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate).~* Current drug-induced psoriasis.~* Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.~* Significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject.~* Hematological abnormalities.~* History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis.~* History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.~* Pregnant or nursing (lactating) women.~* Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIN457150 mg- Induction period Only(IPO) (Type: EXPERIMENTAL): secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)
- AIN457 300 mg - IPO (Type: EXPERIMENTAL): secukinumab- 2 x 150mg injections per dose
- AIN457 150 mg - Fixed Interval (FI) (Type: EXPERIMENTAL): 1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection
- AIN457 300 mg FI (Type: EXPERIMENTAL): 2 s.c. secukinumab 150 mg injections
- AIN457 150 mg- Start of relapse (SoR) (Type: EXPERIMENTAL): 1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection
- AIN457 300 mg- SoR (Type: EXPERIMENTAL): 2 s.c. secukinumab 150 mg injections

Based on this trial design, predict the completion outcome and termination type (if applicable).